What criteria are you using for retreatment with Pluvicto (Lu-177) in those who maintain a good performance status and appropriate lab work?

Mainly, whether or not they've exhausted standard options. At the time I'm answering this, Pluvicto is approved for castration-resistant metastatic disease, either pre- or post-taxane chemotherapy. If they have not had chemo, I usually recommend it. If they have, I get their medical oncologist to we...

The criteria for re-treatment are not yet established, but prospective trials such as RE-LuPSMA (NCT06288113) are underway. Published data from several institutions suggest potential prediction of good re-treatment response in patients with a favorable response to the first regimen of Lu-PSMA, often...

Pluvicto has the largest use in quite advanced disease. Likely its best use will be in earlier relapse, low bulk.

PSA rise either post-prostatectomy (usually earlier) or post XRT (+/- ENI) leads to a PSMA scan. Some grossly disseminated, with ADT or C likely. Other scans may show uptake in the fossa...